...
首页> 外文期刊>Critical care : >Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study
【24h】

Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study

机译:重症监护病房患者中氟康唑,阿尼芬净和卡泊芬净的药代动力学变异性和暴露:来自跨国定义重症监护病房(DALI)患者抗生素水平的数据

获取原文

摘要

IntroductionThe objective of the study was to describe the pharmacokinetics (PK) of fluconazole, anidulafungin, and caspofungin in critically ill patients and to compare with previously published data. We also sought to determine whether contemporary fluconazole doses achieved PK/pharmacodynamic (PD; PK/PD) targets in this cohort of intensive care unit patients.MethodsThe Defining Antibiotic Levels in Intensive care unit patients (DALI) study was a prospective, multicenter point-prevalence PK study. Sixty-eight intensive care units across Europe participated. Inclusion criteria were met by critically ill patients administered fluconazole (n?=?15), anidulafungin (n?=?9), and caspofungin (n?=?7). Three blood samples (peak, mid-dose, and trough) were collected for PK/PD analysis. PK analysis was performed by using a noncompartmental approach.ResultsThe mean age, weight, and Acute Physiology and Chronic Health Evaluation (APACHE) II scores of the included patients were 58?years, 84?kg, and 22, respectively. Fluconazole, caspofungin, and anidulafungin showed large interindividual variability in this study. In patients receiving fluconazole, 33% did not attain the PK/PD target, ratio of free drug area under the concentration-time curve from 0 to 24?hours to minimum inhibitory concentration (fAUC0–24/MIC) ≥100. The fluconazole dose, described in milligrams per kilogram, was found to be significantly associated with achievement of fAUC0–24/MIC ≥100 (P?=?0.0003).ConclusionsConsiderable interindividual variability was observed for fluconazole, anidulafungin, and caspofungin. A large proportion of the patients (33%) receiving fluconazole did not attain the PK/PD target, which might be related to inadequate dosing. For anidulafungin and caspofungin, dose optimization also appears necessary to minimize variability.Electronic supplementary materialThe online version of this article (doi:10.1186/s13054-015-0758-3) contains supplementary material, which is available to authorized users.
机译:简介本研究的目的是描述氟康唑,阿尼芬净和卡泊芬净在危重患者中的药代动力学(PK),并与以前发表的数据进行比较。我们还试图确定在该重症监护室患者队列中当代氟康唑剂量是否达到PK /药效学(PD; PK / PD)目标。方法《重症监护室患者(DALI)研究》中抗生素水平的确定是一项前瞻性,多中心研究,患病率PK研究。欧洲共有68个重症监护病房。危重患者接受氟康唑(n = 15),阿尼芬净(n = 9)和卡泊芬净(n = 7)符合入选标准。收集了三个血液样本(峰值,中剂量和低谷)用于PK / PD分析。结果:入选患者的平均年龄,体重和急性生理与慢性健康评估(APACHE)II评分分别为58岁,84岁和22岁。氟康唑,卡泊芬净和阿尼芬净在这项研究中显示出较大的个体差异。在接受氟康唑的患者中,有33%的患者未达到PK / PD指标,即从0到24小时的浓度-时间曲线到最小抑制浓度(fAUC0-24 / MIC)≥100的自由药物面积比率。发现氟康唑的剂量以毫克每千克表示,与达到fAUC0-24 / MIC≥100(P?=?0.0003)有显着相关。结论观察到氟康唑,阿尼芬净和卡泊芬净的个体差异很大。接受氟康唑的患者中有很大一部分(33%)未达到PK / PD指标,这可能与剂量不足有关。对于阿尼芬净和卡泊芬净,似乎还需要优化剂量以最大程度地减少变异性。电子补充材料本文的在线版本(doi:10.1186 / s13054-015-0758-3)包含补充材料,授权用户可以使用。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号